Mutations in the epidermal growth factor receptor gene in non-small cell lung cancer: Impact on treatment beyond gefitinib and erlotinib
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Epidermal growth factor receptor (EGFR)-activating mutations in non-small cell lung cancer (NSCLC) are molecular targets for treatment with gefitinib and erlotinib, often resulting in improved response and prolonged progression-free survival. Resistance to these drugs, which develops during treatment, is a problem of paramount importance. Several mechanisms of “acquired resistance” have been discovered and treatments for this specific entity are on the horizon.
- Tsao AS, Tang XM, Sabloff B, et al. Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer. J Thorac Oncol. 2006;1:231–239.
- Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361:958–967. CrossRef
- Tanaka T, Matsuoka M, Sutani A, et al. Frequency of and variables associated with the EGFR mutation and its subtypes. Int J Cancer. 2010;126:651–655. CrossRef
- Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947–957. CrossRef
- Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362:2380–2388. CrossRef
- Jackman D, Pao W, Riely GJ, et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol. 2010;28:357–360. CrossRef
- Ciardiello F. Epidermal growth factor receptor inhibitors in cancer treatment. Future Oncol. 2005;1:221–234. CrossRef
- Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129–2139. CrossRef
- Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11:121–128. CrossRef
- Zhou C, Wu Y-L, Chen G, et al. Efficacy results from the randomised phase III OPTIMAL (CTONG0802) study comparing first-line erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM), in Chinese advanced non-small cell lung cancer (NSCLC) with EGFR-activating mutations. Ann Oncol. 2010;21(suppl. 8). Abstract.
- Paz-Ares L, Soulieres D, Melezinek I, et al. Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis. J Cell Mol Med. 2010;14:51–69. CrossRef
- Riely GJ, Pao W, Pham D, et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res. 2006;12:839–844. CrossRef
- Reck M, Van ZN, Gridelli C, et al. Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study. J Thorac Oncol. 2010;5:1616–1622. CrossRef
- Heigener D, Gatzemeier U, Schneider CP, et al. Does the type of EGFR activating mutation impact outcomes with erlotinib treatment? Ann Oncol. 2010;21(suppl. 8). Abstract.
- Nardi V, Azam M, Daley GQ. Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Curr Opin Hematol. 2004;11:35–43. CrossRef
- Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005;352:786–792. CrossRef
- Suda K, Onozato R, Yatabe Y, et al. EGFR T790M mutation: a double role in lung cancer cell survival? J Thorac Oncol. 2009;4:1–4. CrossRef
- Onitsuka T, Uramoto H, Nose N, et al. Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status. Lung Cancer. 2010;68:198–203. CrossRef
- Oxnard GR, Riely GJ, Arcila MG, et al. Clinical course of patients (pts) with acquired resistance (AR) to EGFR tyrosine kinase inhibitors (TKI). J Clin Oncol. 2010;28(suppl.):15s. Abstract.
- Park K, Heo DS, Cho D, et al. PF-00299804 (PF299) in Asian patients (pts) with non-small cell lung cancer (NSCLC) refractory to chemotherapy (CT) and erlotinib (E) or gefitinib (G): a phase (P) I/II study. J Clin Oncol. 2010;28(suppl.). Abstract.
- Mok T, Spigel D, Park K, et al. Efficacy and safety of PF-00299804 (PF299), an oral, irreversible, pan-human epidermal growth factor receptor (pan-HER) tyrosine kinase inhibitor (TKI), as first-line treatment (tx) of selected patients (pts) with advanced (adv) non-small cell lung cancer (NSCLC). J Clin Oncol. 2010;28(suppl.). Abstract.
- Yang CH, Shih JY, Su WP, et al. A phase II study of BIBW 2992 in patients with adenocarcinoma of the lung and activating EGFR mutations (LUXLung 2). J Clin Oncol. 2010;28(suppl.). Abstract.
- Nishino M, Jackman DM, Hatabu H, et al. New response evaluation criteria in solid tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy. AJR Am J Roentgenol. 2010;195:W221–W228. CrossRef
- Miller VA, Hirsh V, Cadranel J, et al. Phase IIB/III double-blind randomized trial of Afatinib (BIBW2992, irreversible inhibitor of EGFR/HER1 and HER2) + best supportive care versus placebo and BSC in patients failing 1–2 lines of chemotherapy and erlotinib or gefitinib (LUXLung 1). Ann Oncol. 2020;21(suppl. 8). Abstract.
- Sequist LV, Besse B, Lynch TJ, et al. Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2010;28:3076–3083. CrossRef
- McDermott U, Settleman J. Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology. J Clin Oncol. 2009;27:5650–5659. CrossRef
- Cipriani NA, Abidoye OO, Vokes E, et al. MET as a target for treatment of chest tumors. Lung Cancer. 2009;63:169–179. CrossRef
- Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039–1043. CrossRef
- Cappuzzo F, Marchetti A, Skokan M, et al. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol. 2009;27:1667–1674. CrossRef
- Munshi N, Jeay S, Li Y, et al. ARQ197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol Cancer Ther. 2010;9:1544–1553. CrossRef
- Schiller JH, Akerley WL, Brugger W, et al.: Results from ARQ197-209: a global randomized placebocontrolled phase II clinical trial of erlotinib plus ARQ197 versus erlotinib plus placebo in previously treated EGFR inhibitor-naive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol. 2010;28:15s. Abstract. CrossRef
- Spigel D, Ervin T, Ramlau R, et al. Randomised multicenter double-blind placebo controlled phase II study evaluating METMAB, an antibody to METreceptor in combination with erlotinib in patients with advanced non-small cell lung cancer. Ann Oncol. 2010;21(suppl. 18). Abstract.
- Morgillo F, Kim WY, Kim ES, et al. Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clin Cancer Res. 2007;13:2795–2803. CrossRef
- Karp DD, Paz-Ares LG, Novello S, et al. Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol. 2009;27:2516–2522. CrossRef
- Jassem J, Langer CJ, Karp DD, et al. Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC). J Clin Oncol 2010;28(suppl.). Abstract 7500.
- Mutations in the epidermal growth factor receptor gene in non-small cell lung cancer: Impact on treatment beyond gefitinib and erlotinib
Advances in Therapy
Volume 28, Issue 2 , pp 126-133
- Cover Date
- Print ISSN
- Online ISSN
- Springer Healthcare Communications
- Additional Links
- non-small cell lung cancer
- Industry Sectors